博安生物(06955.HK)公布,公司自主研发的度拉糖肽注射液(BA5101)的上市申请已获中华人民共和国国家药品监督管理局药品审评中心受理。
本文源自金融界AI电报
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.